Nascent Biotech (NBIO) 10-Q 14 Feb 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2021	Feb. 14, 2022
Cover [Abstract]
Entity Registrant Name	NASCENT BIOTECH INC
Entity Central Index Key	0001622057
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		107,728,175
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-55299
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	46-5001940
Entity Address Address Line 1	623 17th Street Suite 4
Entity Address City Or Town	Vero Beach
Entity Address State Or Province	FL
Entity Address Postal Zip Code	32960
City Area Code	612
Local Phone Number	961-5656
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Current assets
Cash	$ 1,737	$ 1,435
Accounts receivable	750,000	750,000
Total current assets	751,737	751,435
Total assets	751,737	751,435
Current liabilities
Accounts payable and accrued liabilities	788,834	636,831
Convertible note net of discount	165,435	161,736
Derivative liability	95,238	302,156
Due to related parties	150,220	123,217
Total current liabilities	1,199,727	1,223,940
Total liabilities	1,199,727	1,223,940
Commitments and contingencies	0	0
Stockholders deficit
Preferred stock, 0.001 par value, 50,000,000 authorized, none and 54,130 issued and outstanding, respectively	0	54
Common stock, 0.001 par value; 500,000,000 authorized, 107,728,175 and 104,834,083 issued and outstanding, respectively	107,728	104,834
Additional paidin capital	17,859,481	17,774,023
Accumulated deficit	(18,415,199)	(18,351,416)
Total stockholders deficit	(447,990)	(472,505)
Total liabilities and stockholder deficit	$ 751,737	$ 751,435

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Mar. 31, 2021
Stockholders deficit
Preferred stock shares par value	$ 0.001	$ 0.001
Preferred stock shares authorized	50,000,000	50,000,000
Preferred stock shares issued	0	54,130
Preferred stock shares outstanding	0	54,130
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	107,728,175	104,834,083
Common stock shares outstanding	107,728,175	104,834,083

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
License fee income	$ 1,000,000	$ 0	$ 1,000,000	$ 0
Operating expenses
Consulting	108,000	409,111	388,813	1,129,846
General and administrative expense	70,538	91,923	309,861	260,106
Research and development	190,487	53,903	343,398	277,338
Income (loss) from operations	630,975	(554,937)	(42,072)	(1,667,290)
Other income (expense)
Interest income	0	1	10	4
Change in fair value of derivative liability	57,703	(73,810)	373,585	566,220
Gain on debt settlement	0	0	5,000	0
Financing costs	0	(31,356)	(101,150)	(34,356)
Debt discount interest	(86,314)	(4,423)	(287,979)	(4,423)
Interest expense	(5,041)	(54,981)	(11,177)	(201,927)
Total other income (expense)	(33,652)	(164,570)	(21,711)	325,518
Net income (loss)	$ 597,323	$ (719,507)	$ (63,783)	$ (1,341,772)
Net loss per share basic	$ 0.01	$ (0.01)	$ 0	$ (0.02)
Net loss per share dilutive	$ 0.01	$ (0.01)	$ 0	$ (0.02)
Weighted average number of shares outstanding basic	107,728,175	76,566,884	107,471,003	64,027,487
Weighted average number of shares outstanding dilutive	112,358,175	76,566,884	107,471,003	64,027,487

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (Unaudited) - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance shares at Mar. 31, 2020		60,000	44,890,262
Balance amount at Mar. 31, 2020	$ (2,875,704)	$ 60	$ 44,890	$ 13,916,995	$ (16,837,649)
Common stock issued for related parties for service shares			2,007,000
Common stock issued for related parties for service amount	190,915		$ 2,007	188,908
Common stock issued for AP related parties shares			13,831,101
Common stock issued for AP related parties amount	1,387,872		$ 13,831	1,374,041
Common stock issued for AP settlement shares			35,715
Common stock issued for AP settlement amount	5,000		$ 36	4,964
Common stock issued for service shares			677,000
Common stock issued for service amount	85,440		$ 677	84,763
Common stock issued for preferred shares shares		(60,000)	1,352,529
Common stock issued for preferred shares amount	13,011	$ (60)	$ 1,354	11,717
Net loss	(203,971)				(203,971)
Balance shares at Jun. 30, 2020			62,793,607
Balance amount at Jun. 30, 2020	(1,397,437)		$ 62,795	15,581,388	(17,041,620)
Balance shares at Mar. 31, 2020		60,000	44,890,262
Balance amount at Mar. 31, 2020	(2,875,704)	$ 60	$ 44,890	13,916,995	(16,837,649)
Common stock issued for service amount	144,591
Net loss	(1,341,772)
Balance shares at Dec. 31, 2020		250,000	91,330,154
Balance amount at Dec. 31, 2020	(1,231,924)	$ 250	$ 91,330	16,855,917	(18,179,421)
Balance shares at Jun. 30, 2020			62,793,607
Balance amount at Jun. 30, 2020	(1,397,437)		$ 62,795	15,581,388	(17,041,620)
Common stock issued for service shares			728,572
Common stock issued for service amount	44,151		$ 728	43,423
Net loss	(418,294)				(418,294)
Preferred shares issued for cash shares		640,000
Preferred shares issued for cash amount	640,000	$ 640		639,360
Preferred shares issued for debt shares		100,000
Preferred shares issued for debt amount	100,000	$ 100		99,900
Common stock issued for servicerelated parties shares			918,115
Common stock issued for servicerelated parties amount	64,268		$ 918	63,350
Common stock issued for convertible debt shares			2,677,397
Common stock issued for convertible debt amount	150,000		$ 1,677	147,323
Common stock issued for accounts payable shares			63,000
Common stock issued for accounts payable amount	6,300		$ 63	6,237
Balance shares at Sep. 30, 2020		740,000	67,180,691
Balance amount at Sep. 30, 2020	(811,012)	$ 740	$ 67,181	16,580,981	(17,495,914)
Common stock issued for related parties for service shares			4,784,460
Common stock issued for related parties for service amount	224,028		$ 4,784	219,244
Common stock issued for service shares			245,902
Common stock issued for service amount	15,000		$ 246	14,754
Net loss	(719,507)				(719,507)
Common stock issued for convertible debt shares			1,304,782
Common stock issued for convertible debt amount	49,567		$ 1,305	48,262
Common stock issued for conversion of preferred shares		(490,000)	17,814,319
Common stock issued for conversion of preferred amount	10,000	$ (490)	$ 17,814	(7,324)
Balance shares at Dec. 31, 2020		250,000	91,330,154
Balance amount at Dec. 31, 2020	(1,231,924)	$ 250	$ 91,330	16,855,917	(18,179,421)
Balance shares at Mar. 31, 2021		54,130	104,834,083
Balance amount at Mar. 31, 2021	(472,505)	$ 54	$ 104,834	17,774,023	(18,351,416)
Common stock issued for AP related parties shares			307,010
Common stock issued for service shares			50,000
Common stock issued for service amount	5,250		$ 50	5,200
Common stock issued for preferred shares shares		(54,130)	1,968,363
Common stock issued for preferred shares amount		$ (54)	$ 1,968	(1,914)
Net loss	(450,076)				(450,076)
Common stock issued to related parties shares			568,719
Common stock issued to related parties amount	59,716		$ 569	59,147
Common stock issued for AP related parties amount	23,332		$ 307	23,025
Balance shares at Jun. 30, 2021			107,728,175
Balance amount at Jun. 30, 2021	(834,283)		$ 107,728	17,859,481	(18,801,492)
Balance shares at Mar. 31, 2021		54,130	104,834,083
Balance amount at Mar. 31, 2021	(472,505)	$ 54	$ 104,834	17,774,023	(18,351,416)
Common stock issued for service amount	5,250
Net loss	(63,783)
Balance shares at Dec. 31, 2021			107,728,175
Balance amount at Dec. 31, 2021	(447,990)		$ 107,728	17,859,481	(18,415,199)
Balance shares at Jun. 30, 2021			107,728,175
Balance amount at Jun. 30, 2021	(834,283)		$ 107,728	17,859,481	(18,801,492)
Net loss	(211,030)				(211,030)
Balance shares at Sep. 30, 2021			107,728,175
Balance amount at Sep. 30, 2021	(1,045,313)		$ 107,728	17,859,481	(19,012,522)
Net loss	597,323				597,323
Balance shares at Dec. 31, 2021			107,728,175
Balance amount at Dec. 31, 2021	$ (447,990)		$ 107,728	$ 17,859,481	$ (18,415,199)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (63,783)	$ (1,341,772)
Adjustments to reconcile net loss to net cash used in operating activities
Stock based compensation related parties	59,716	479,212
Stock-based compensation	5,250	144,591
(Gain) loss in fair value of derivative liability	(373,585)	(566,220)
Debt discount expense	287,979	178,652
Changes in operating assets and liabilities
Accounts payable and accrued expenses	154,891	(26,294)
Prepaid	0	(18,313)
Due to related parties	50,335	311,598
Net cash provided by (used in) operating activities	120,803	(838,546)
Cash flows from financing activities
Proceeds from the sale of preferred shares for cash	0	640,000
Proceeds from convertible notes	200,000	200,000
Repayment of convertible notes	(320,500)	0
Proceeds from notes payable	0	50,000
Net cash provided (used) by financing activities	(120,500)	890,000
Net increase (decrease) in cash	303	51,454
Cash beginning of year	1,434	3,218
Cash end of period	1,737	54,672
SUPPLEMENT DISCLOSURES
Interest paid	20,055	0
Income taxes paid	0	0
Non Cash Transactions
Common stock issued for conversion of preferred shares	1,968	23,560
Common stock issued for accrued expenses related party	23,332	1,387,872
Common stock issued for accounts payable	0	11,300
Common stock issued for convertible debt	0	199,567
Common stock issued for notes payable	$ 0	$ 100,000

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	9 Months Ended
	Dec. 31, 2021
ORGANIZATION AND NATURE OF OPERATIONS
ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Nascent Biotech, Inc. (“Nascent” or the “Company”) was incorporated on March 3, 2014, under the laws of the State of Nevada. The Company is actively developing Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Pritumumab has shown to be very effective at low doses in previous clinical studies in Japan. Nascent is a Phase 1 clinical stage biopharmaceutical company that focuses on biologic drug candidates that are being clinical tested for the treatment of brain and pancreatic cancer. On March 31, 2017, the Company filed its IND submission with the United States Food and Drug Administration (FDA) for clearance to begin Phase I clinical trials. On December 7, 2018, the Company received a letter from the FDA allowing it to use a specific lot of drug substance to begin phase 1 clinical trial. On March 15, 2021, the Company opened phase one clinical trials. The trial is a dose escalation trial to determine toxicity levels of the drug with patients. As of December 31, 2021, the trials are open to the third cohort of patients with the dose escalation to 8.0mg/kg. Phase 1 of the trial will complete after the fourth cohort with dosage of 12mg/kg is completed. After its completion, the data will be submitted to the FDA for approval to commence phase 2 of the clinical trial studies.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Dec. 31, 2021
BASIS OF PRESENTATION
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. The accompanying unaudited interim consolidated financial statements of the Company for the nine months ended December 31, 2021 and 2020 have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information in accordance with Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the year ended March 31, 2021. In the opinion of management, the unaudited financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial position and the results of operations for the interim periods presented herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for any subsequent quarters or for an entire year. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous release’s guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. Basis of Presentation The Company computes net loss per share in accordance with ASC 260, Earnings per Share We have identified the conversion features of certain of our convertible notes payable as derivatives. We estimate the fair value of the derivatives using the American Option Binomial Lattice pricing model. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility and variable conversion prices based on market prices as defined in the respective agreements. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. Reclassification Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. The reclassifications have no effect on the net loss or stockholders deficit . Revenue recognition In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company has one revenue stream, which is the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met. Accounts receivable Accounts receivables are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the three and nine months ended December 31, 2021, and 2020, respectively. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Financial assets and liabilities recorded at fair value in our condensed consolidated balance sheets are categorized based upon a fair value hierarchy established by GAAP, which prioritizes the inputs used to measure fair value into the following levels: Level 1– Quoted market prices in active markets for identical assets or liabilities at the measurement date. Level 2– Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data. Level 3– Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Dec. 31, 2021
GOING CONCERN
NOTE 3 - GOING CONCERN	NOTE 3 - GOING CONCERN The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has a working capital deficit and has incurred losses from operations. The Company has received limited revenue through the sale of a license agreement to cover its operating costs and the Company will incur additional expenses in the future developing their product. These factors raise substantial doubt about the company’s ability to continue as a going concern. The Company engages in research and development activities that must be satisfied in cash secured through outside funding. The Company may offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Dec. 31, 2021
GOING CONCERN
RELATED PARTY TRANSACTIONS	NOTE 4 – RELATED PARTY TRANSACTIONS On September 1, 2015, the Company entered five-year employment contracts with three of its officers and directors. One of the officers and director resigned as of September 30, 2020. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares, so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company. The following table sets forth the shares earned under these contracts for the two active officers as of December 31, 2021: Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 7,177,269 8,206,179 Chief Financial Officer 617,346 3,821,223 4,438,569 Total 1,646,256 10,998,492 12,644,748 On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares, so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company Officer and Director Fiscal Year Annualized Compensation Being Paid President $ 250,000 Chief Financial Officer $ 180,000 Total $ 430,000 As of December 31, 2021, the Company accrued $150,220 due to related parties. During the nine months ended December 31, 2020 four officers and directors were issued 7,709,575 shares of common stock with a value of $479,212 for service. During the nine months period ended December 31, 2020 three officers of the Company converted $1,387,872 of accrued compensation into 13,831,101 shares of common stock of the Company. During the nine month period ended December 31, 2020 the Company paid the related parties (three officers and directors) $89,000 in consulting fees in cash and accrued $193,333 of the consulting fees for a total of $282,333. In addition $14,000 in expenses were accrued for the related parties. During the nine months ended December 31, 2021, three officers and directors were issued 568,719 shares of common stock with a value of $59,716 for service. During the nine months period ended December 31, 2021 a director of the Company converted $23,332 of accrued compensation into 307,010 shares of common stock of the Company. During the nine months period ended December 31, 2021, the Company issued 50,000 shares of common stock with a value of $5,250 for service. During the nine months period ended December 31, 2021, 54,130 shares of preferred stock were converted into 1,968,363 shares of common stock. The conversion eliminated all outstanding convertible preferred shares.

EQUITY

EQUITY	9 Months Ended
	Dec. 31, 2021
EQUITY
EQUITY	NOTE 5 – EQUITY Preferred On July 25, 2019, the Company issued 110,000 shares of series A convertible preferred to one entity with a value of $110,000 for cash. Each share of series A preferred is convertible after 180 days to four shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares plus 7% per annum interest. During the nine months period ended December 31, 2020 the Company issued 740,000 shares of Series A preferred stock and 3,700,000 warrants; 640,000 for $640,000 in cash and $100,000 for debt. The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance. In addition the Company agreed to filing an S-1 by September 21, 2020 for the common stock to be converted and the underlying common shares for the warrants. The S-1 has not been filed. During the nine months ended December 31, 2020 the Company issued 17,714,319 shares of common stock for the conversion of 490,000 shares of preferred stock and $8,400 in interest. On April 1, 2021, 54,130 shares of preferred stock were converted into 1,968,363 shares of common stock. The conversion eliminated all outstanding convertible preferred shares. Common During the nine months ended December 31, 2020 the Company issued 98,715 shares of common stock with a value of $11,300 for settlement of accounts payable. During the nine months ended December 31, 2020 the Company issued 1,651,474 shares of common stock with a value of $144,591 for service. During the nine months ended December 31, 2020 the Company issued 19,166,848 shares of common stock for the conversion of 550,000 shares of preferred stock. During the nine months ended December 31, 2020 three officers and a director were issued 7,709,575 shares of common stock with a value of $479,212 for service. During the nine months ended December 31, 2020, the Company issued 3,982,179 shares of common stock for the conversion of $199,566 of convertible debt and fees. During the nine months period ended December 31, 2020 three officers of the Company converted $1,387,872 of accrued compensation into 13,831,101 shares of common stock of the Company. During the nine months ended December 31, 2021, three officers and directors were issued 568,719 shares of common stock with a value of $59,716 for service. During the nine months period ended December 31, 2021, a director of the Company converted $23,332 of accrued compensation into 307,010 shares of common stock of the Company. During the nine months ended December 31, 2021, the Company issued 50,000 shares of common stock with a value of $5,250 for service

OPTIONS

OPTIONS	9 Months Ended
	Dec. 31, 2021
OPTIONS
OPTIONS	NOTE 6– OPTIONS As of December 31, 2021, there was no option expenses recognized by the Company and the balance of unrecognized option expense was zero. In addition 475,000 options expired for the resignation of an officer and director plus the termination of consultants holding options that were not converted in the required time period after termination. The following sets forth the options granted and outstanding during the nine months ended December 31, 2021: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2021 1,405,000 $ 0.34 4.80 1,405,000 $ -- Granted -- -- -- -- -- Exercised Expired (475,000 ) -- (475,000 ) -- Outstanding at December 31, 2021 930,000 $ 0.379 4.05 930,000 $ -- The weighted average remaining life and intrinsic value of the options as of December 31, 2021, was 4.05 years and zero, respectively.

WARRANTS

WARRANTS	9 Months Ended
	Dec. 31, 2021
WARRANTS
WARRANTS	NOTE 7 – WARRANTS During the year ended March 31, 2021, the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares. The warrants expire in two years from grant date and are convertible into common stock at $0.15 per share. The warrants contain an anti-dilution clause which become effective if any instrument is issued after the warrant issuance is converted into common stock at a price lower than the warrant conversion price. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date, using the following key inputs: market prices of the Company’s common stock at dates of grant between $0.08-0.11 per share, conversion price of $0.15, volatility of 312.5%-314.49% and discount rate of 0.14-0.16%. Based on the fair value of the common stock of $437,000 and value of the warrants of $349,605 the fair value of the warrants was calculated to be 41% of the total value or $303,000. During the year ended March 31, 2021, the valuation resulted in a deemed dividend from the down round calculation of $555,000. The weighted average remaining life and intrinsic value of the warrants as of December 31, 2021, was Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2020 - $ 0.00 0.00 $ - Granted 3,700,000 0.15 2.00 Exercised - - - - Expired - - - - Outstanding at March 31, 2021 3,700,000 $ 0.04 1.35 $ - Granted - - - - Exercised - - - - Expired - - - - Outstanding as of December 31, 2021 3,700,000 $ 0.04 0.60 $ -

CONVERTIBLE DEBT

CONVERTIBLE DEBT	9 Months Ended
	Dec. 31, 2021
CONVERTIBLE DEBT
CONVERTIBLE DEBT	NOTE 8 - CONVERTIBLE DEBT On May 7, 2020, the Company issued an 8% $50,000 one year convertible note. The note is convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion. On July 7, 2020, $50,000 of the one-year convertible note payable was converted into 50,000 shares of series A preferred shares. On October 28, 2020, the Company issued a $138,000 convertible note with an OID of $10,000. The note matures on October 28, 2021 and bears interest at 10% per annum. After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years. On April 20, 2021, note was paid with the principal of $138,000, accrued interest of $6,805 and financing costs of $41,400. On November 11, 2020, the Company issued a $82,500 convertible note with an OID of $7,500. The note matures on October 28,2021 with a fixed interest of 10%. After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion. On April 22, 2021, the note was paid consisting of principal of $82,500, accrued interest of $8,250 and finance costs of $24,750. On February 16, 2021, the Company issued a $100,000 convertible note with an OID of $5,000. The note matures on February 16, 2022, and bears fixed interest of 10%. After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years. On August 16, 2021, the note was paid consisting of principal of $100,000, accrued interest of $5,000 and financing costs off $35,000. On August 10, 2021, the Company issued a $200,000 convertible note. The note matures on February 10, 2022, and bears fixed interest of 10%. Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note may be converted into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years. As of December 31, 2021 the derivative was calculated using risk free interest of 0.05%, volatility of 153% and expected life of .11. The outstanding balance due as of December 31, 2021 was $200,000 principal and interest accrued of $7,671.

FAIR VALUE MEASUREMENTS AND DER

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	9 Months Ended
	Dec. 31, 2021
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	NOTE 9 - FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level – 1 Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level – 2 Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level – 3 Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value As of December 31, 2021, the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the nine months ended December 31 2021: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Additions at fair value 166,667 Change in fair value of the derivative - - (373,585 ) Balance at December 31, 2021 $ - $ - $ 95,238 The estimated fair value of the derivative liabilities at December 31, 2021 was calculated using the Binomial Lattice pricing model with the following assumptions: Risk-free interest rate .05 % Expected life in years 0.11 Dividend yield 0 % Expected volatility 153.00 %

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2021
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 10 –COMMITMENTS AND CONTINGENCIES On September 30, 2016, the Company entered a cell line sales agreement with the product manufacturer. Under the terms of the agreement the Company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a Product; 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a Product; 3. $225,000 payable upon the first Biologics License Application approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000; 5. A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly. On June 29, 2021, the Company paid $25,000 of the outstanding balance. As of December 31, 2021, $299,960 was due for the annual maintenance fee, first patient dosage of phase 1 plus interest. On March 9, 2020, the Board of Directors of the Company adopted an expense bonus program. Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocated 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors.

LICENSE AGREEMENT

LICENSE AGREEMENT	9 Months Ended
	Dec. 31, 2021
LICENSE AGREEMENT
LICENSE AGREEMENT	NOTE 11- LICENSE AGREEMENT On March 31, 2021, the Company issued a license agreement for US $5,000,000 to BioRay Pharmaceutical Co, LTD, licensing Pritumumab internationally with the exclusion of North and Central America and the Caribbean Islands. Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials, which started in March 2021. In addition, the Company will receive $750,000 upon the enrollment of the 12th patient or the escalation to cohort 3 dosage level of 8.0 mg/kg, whichever is achieved first. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin. Upon commercialization by the Licensee, the Company will receive a 9% royalty on net sales for 20 years. As of December 17, 2021 the Company had completed cohort 2 and escalated to cohort 3 at which milestone invoiced the licensee for the $750,000 payment.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2021
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 12 - SUBSEQUENT EVENTS On February 9, 2022 the Company received the second milestone license payment of $750,000, The Company has evaluated subsequent events to determine events occurring after December 31, 2021, through February 14, 2022 that would have a material impact on the Company’s financial results or require disclosure and have determined none exist other than those noted above in this footnote.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Dec. 31, 2021
BASIS OF PRESENTATION
Recent Accounting Pronouncements	In February 2016, the FASB issued ASU No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous release’s guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
Basis of Presentation	The Company computes net loss per share in accordance with ASC 260, Earnings per Share We have identified the conversion features of certain of our convertible notes payable as derivatives. We estimate the fair value of the derivatives using the American Option Binomial Lattice pricing model. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility and variable conversion prices based on market prices as defined in the respective agreements. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.
Reclassification	Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. The reclassifications have no effect on the net loss or stockholders deficit .
Revenue recognition	In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company has one revenue stream, which is the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met.
Accounts receivable	Accounts receivables are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the three and nine months ended December 31, 2021, and 2020, respectively.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Financial assets and liabilities recorded at fair value in our condensed consolidated balance sheets are categorized based upon a fair value hierarchy established by GAAP, which prioritizes the inputs used to measure fair value into the following levels: Level 1– Quoted market prices in active markets for identical assets or liabilities at the measurement date. Level 2– Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data. Level 3– Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Dec. 31, 2021
RELATED PARTY TRANSACTIONS (Tables)
Schedule of shares earned by related party
Schedule of annual salary and annual severance amounts	Officer and Director Fiscal Year Annualized Compensation Being Paid President $ 250,000 Chief Financial Officer $ 180,000 Total $ 430,000

OPTIONS (Tables)

OPTIONS (Tables)	9 Months Ended
	Dec. 31, 2021
OPTIONS
Schedule of Summary of stock options aoutstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2021 1,405,000 $ 0.34 4.80 1,405,000 $ -- Granted -- -- -- -- -- Exercised Expired (475,000 ) -- (475,000 ) -- Outstanding at December 31, 2021 930,000 $ 0.379 4.05 930,000 $ --

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Dec. 31, 2021
WARRANTS
Schedule of Summary of warrants outstanding	Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2020 - $ 0.00 0.00 $ - Granted 3,700,000 0.15 2.00 Exercised - - - - Expired - - - - Outstanding at March 31, 2021 3,700,000 $ 0.04 1.35 $ - Granted - - - - Exercised - - - - Expired - - - - Outstanding as of December 31, 2021 3,700,000 $ 0.04 0.60 $ -

FAIR VALUE MEASUREMENTS AND D_2

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Tables)	9 Months Ended
	Dec. 31, 2021
WARRANTS
Schedule of estimated fair value	Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Additions at fair value 166,667 Change in fair value of the derivative - - (373,585 ) Balance at December 31, 2021 $ - $ - $ 95,238
Schedule of summarize of change in the fair value of the derivative liabilities	Risk-free interest rate .05 % Expected life in years 0.11 Dividend yield 0 % Expected volatility 153.00 %

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative)	Dec. 31, 2021shares
BASIS OF PRESENTATION
Options	930,000
Shares outstnading	107,728,175
Warrants	3,700,000
Total shares	112,358,175

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	9 Months Ended
	Dec. 31, 2021shares
Initial Share Awards Under the Contracts	1,646,256
Additional Shares Earned to Maintain Ownership Percentage	10,998,492
Total Shares Earned	12,644,748
President [Member]
Initial Share Awards Under the Contracts	1,028,910
Additional Shares Earned to Maintain Ownership Percentage	7,177,269
Total Shares Earned	8,206,179
Chief Financial Officer [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	3,821,223
Total Shares Earned	4,438,569

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	12 Months Ended
	Mar. 31, 2021USD ($)
Fiscal Year Annualized Compensation Being Paid	$ 430,000
President [Member]
Fiscal Year Annualized Compensation Being Paid	250,000
Chief Financial Officer [Member]
Fiscal Year Annualized Compensation Being Paid	$ 180,000

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021
Due to Related Party					$ 150,220		$ 123,217
Debt Conversion, Converted Instrument, Shares Issued					1,968,363
Preferred stock, shares issued upon conversion					54,130
Common stock shares issued for services, shares					50,000	1,651,474
Common stock shares issued for services, amount	$ 5,250	$ 15,000	$ 44,151	$ 85,440	$ 5,250	$ 144,591
Common stock issued for accrued expenses- related party					$ 23,332	$ 1,387,872
September 1, 2020 [Member]
Officers and directors employment agreement terms, description					Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares, so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company
Officer And Director [Member]
Consulting fees in cash					$ 89,000
Accrued Fees					193,333
Consulting Fees Total					282,333
Accrued Expence For the Relared Party					$ 14,000
Four Officers and Director [Member]
Common stock shares issued for services, shares					568,719	7,709,575
Common stock shares issued for services, amount					$ 59,716	$ 479,212
Three Officers And Director [Member] | September 1, 2015 [Member]
Officers and directors employment agreement terms, description					the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares, so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company.
Three Officers [Member]
Common stock issued for accrued expenses- related party						$ 1,387,872
Common stock shares issued for compensation						13,831,101
Director [Member]
Common stock issued for accrued expenses- related party					$ 23,332
Common stock shares issued for compensation					307,010

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	Jul. 07, 2020	Jul. 25, 2019	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021
Common stock shares issued for services, shares							50,000	1,651,474
Common stock issued for accounts payable, shares								98,715
Common stock issued for accounts payable								$ 11,300
Common stock issued for convertible debt, shares								3,982,179
Common stock shares value for services, amount			$ 5,250	$ 15,000	$ 44,151	$ 85,440	$ 5,250	$ 144,591
Common stock issued for convertible debt, amount								199,566
Common stock issued for accrued expenses- related party							23,332	1,387,872
Debt Conversion, Converted Instrument, Amount							$ 0	$ 100,000
Preferred stock, shares issued							0		54,130
April 1, 2021 [Member]
Common stock issued for accounts payable, shares							54,130
Preferred stock, shares issued during period							1,968,363
Preferred [Member]
Common stock issued for accounts payable, shares								550,000
Preferred stock, shares issued during period								740,000
Debt Conversion, Converted Instrument, Warrants Issued								3,700,000
Debt Conversion, Converted Instrument, Amount								$ 100,000
Debt Conversion, Converted Instrument, Cash								$ 640,000
Debt Conversion, Converted Instrument, Converted Shares								640,000
Debt Conversion, Converted Instrument, Conversion price								$ 0.15
Series A Convertible Preferred Stock [Member]
Common stock issued for accounts payable, shares								490,000
Preferred stock, shares issued during period								17,714,319
Debt Conversion, Converted Instrument, Amount	$ 50,000
Preferred Stock, Interest								$ 8,400
Preferred stock, shares issued		110,000
Conversion description		Each share of series A preferred is convertible after 180 days to four shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares plus 7% per annum interest.
Preferred stock shares, value		$ 110,000
Four Officers and Director [Member]
Common stock shares issued for services, shares							568,719	7,709,575
Common stock shares value for services, amount							$ 59,716	$ 479,212
Three Officers [Member]
Common stock shares issued for compensation								13,831,101
Common stock issued for accrued expenses- related party								$ 1,387,872
Director [Member]
Common stock shares issued for compensation							307,010
Common stock issued for accrued expenses- related party							$ 23,332

OPTIONS (Details)

OPTIONS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Options
Number of option exercisable, Beginning	1,405,000
Number of option exercisable, Expired	(475,000)
Number of option exercisable, Ending	930,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.34
Weighted average exercise price, Granted	0
Weighted average exercise price, Exercised	0
Weighted average exercise price, Expired	0
Weighted average exercise price, Ending	$ 0.379
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	4 years 9 months 18 days
Weighted Average Remaining Contract life, Ending	4 years 18 days
Number of option exercisable
Outstanding option, Beginning	1,405,000
Outstanding option, Expired	(475,000)
Outstanding option, Ending	930,000
Intrinsic value
Intrinsic value, Granted	$ 0
Intrinsic value, Exercised	0	$ 0
Intrinsic value, Ending	$ 0

OPTIONS (Details Narrative)

OPTIONS (Details Narrative)	9 Months Ended
	Dec. 31, 2021USD ($)
OPTIONS (Details)
Options expired that were not converted in the required time period after termination	$ 475,000
Intrinsic value, Ending	$ 0
Weighted average remaining life and intrinsic value	4 years 18 days

WARRANTS (Details)

WARRANTS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Number of warrants
Outstanding warrants, Beginning	3,700,000	0
Outstanding warrants, granted	0	3,700,000
Outstanding warrants, Expired	0	0
Outstanding warrants, Exercised	0	0
Outstanding warrants, Ending	3,700,000	3,700,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.04	$ 0
Weighted average exercise price, Granted	0	0.15
Weighted average exercise price, Expired	0	0
Weighted average exercise price, Exercised	0	0
Weighted average exercise price, Ending	$ 0.04	$ 0.04
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	1 year 4 months 6 days
Weighted Average Remaining Contract life, Granted		2 years
Weighted Average Remaining Contract life, Ending	1 year 4 months 6 days	7 months 6 days
Intrinsic value
Intrinsic value, Beginning		$ 0
Intrinsic value, Granted	$ 0
Intrinsic value, Exercised	0	0
Intrinsic value, Expired	0	0
Intrinsic value, Ending	$ 0	$ 0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Deemed dividend from down round		$ 555,000
Volatility rate	153.00%
Warrant [Member]
Exercise price of warrants	$ 0.15
Fair value of warrants	$ 349,605
Total value of warrant	303,000
Fair value of common stock	$ 437,000
Warrants conversion price	$ 0.15
Warrants descriptions		the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares
Maximum [Member] | Warrant [Member]
Exercise price of warrants	$ 0.11
Volatility rate	314.49%
Discount rate	0.16%
Minimum [Member] | Warrant [Member]
Exercise price of warrants	$ 0.08
Volatility rate	312.50%
Discount rate	0.14%

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)	Aug. 10, 2021	Nov. 11, 2020	Jul. 07, 2020	May 07, 2020	Aug. 16, 2021	Apr. 20, 2021	Feb. 16, 2021	Oct. 28, 2020	Dec. 31, 2021	Dec. 31, 2020
Repayment of debt									$ 320,500	$ 0
Common stock shares issued upon conversion of debt									54,130
Debt instrument converted amount									$ 0	$ 100,000
Risk free interest rate									0.05%
8% Convertible Note [Member]
Convertible debt				$ 50,000
Conversion price, Description				The note is convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion
Series A Convertible Preferred Stock [Member]
Financing cost		$ 24,750			$ 35,000	$ 41,400
Repayment of debt		82,500			100,000	138,000
Accrued interest		82,500			$ 5,000	$ 6,805			$ 7,671
Common stock shares issued upon conversion of debt			50,000
Debt instrument converted amount			$ 50,000
Convertible debt	$ 200,000	$ 82,500					$ 100,000	$ 138,000	$ 200,000
Conversion price, Description		After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion.					After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years	After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years
Debt instrument original issue discount		$ 7,500					$ 5,000	$ 10,000
Risk free interest rate	0.05%	10.00%					10.00%		0.05%
Expected volatility	132.00%								153.00%
Debt maturity date	Feb. 10, 2022	Oct. 28, 2021					Feb. 16, 2022	Oct. 28, 2021
Interest rate	10.00%							10.00%

FAIR VALUE MEASUREMENTS AND D_3

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Details)	9 Months Ended
	Dec. 31, 2021USD ($)
Fair Value, Inputs, Level 1 [Member]
Begnning Balance	$ 0
Change in fair value of the derivative	0
Ending Balance	0
Fair Value, Inputs, Level 2 [Member]
Begnning Balance	0
Change in fair value of the derivative	0
Ending Balance	0
Fair Value, Inputs, Level 3 [Member]
Begnning Balance	302,156
Additions at fair value	166,667
Change in fair value of the derivative	(373,585)
Ending Balance	$ 95,238

FAIR VALUE MEASUREMENTS AND D_4

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Details 1)	9 Months Ended
	Dec. 31, 2021
LICENSE AGREEMENT
Risk-free interest rate	0.05%
Dividend yield	0.00%
Expected life in years	1 month 9 days
Expected volatility	153.00%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Mar. 09, 2020	Sep. 30, 2016	Dec. 31, 2021	Jun. 29, 2021
Merger, description	Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors
Annual Maintenance			$ 299,960
Notes payable, outstanding balance				$ 25,000
Investment description		A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly
First BLA [Member]
Future payments		$ 225,000
First Phase III clinical trial [Member]
Future payments		225,000
First Phase I clinical trial [Member]
Future payments		100,000
Annual maintenance fee		$ 50,000

LICENSE AGREEMENT (Details Narr

LICENSE AGREEMENT (Details Narrative) - BioRay Pharmaceutical Co LTD [Member] - USD ($)	1 Months Ended
	Mar. 31, 2021	Dec. 31, 2021
Agreement description	Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials, which started in March 2021. In addition, the Company will receive $750,000 upon the enrollment of the 12th patient or the escalation to cohort 3 dosage level of 8.0 mg/kg, whichever is achieved first. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin.
Issuance of license agreement	$ 5,000,000
License Payment		$ 750,000
Royalty rate	9.00%
Net sales	20 years

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	Feb. 09, 2022USD ($)
SUBSEQUENT EVENTS
License Payment	$ 750,000